BrightOwl Loader Loading

Internal Quality Auditor - United Kingdom  

Company managed [?] Still accepting applications

Posted on : 19 May 2017

Project Description

Responsibilities
  • For nearly 70 years, our company employees have worked together to assist in the discovery, development and safe manufacture of new drug therapies. 
  • When you join our family, you will have a significant impact on the health and well-being of people across the globe. 
  • Whether your background is in life sciences, finance, IT, sales or another area, your skills will play an important role in the work we perform. 
  • In return, we’ll help you build a career that you can feel passionate about.
  • We are seeking an experienced Internal Quality Auditor for our Discovery Services site.
  • The Internal Quality Auditor will co-ordinate and carry out a programme of internal quality audits across all Early Discovery sites. 
  • When requested, they will carry out root cause or other suitable investigations into incidents and facilitate departments identifying solutions to non-conformities. They will also carry out vendor audits either remotely or at the  site. 
  • The Internal Quality Auditor will be an example in quality matters and recommend improvements to the Early Discovery Quality Management System. 




Responsibilities:
The following are minimum requirements related to the Internal Quality Auditor position. 
  • Evidence of qualification/training as a quality auditor; BSc in a relevant discipline
  • Experience of auditing non GxP quality systems (Business Excellence , ISO 9001 etc.) in a scientific environment 
  • Familiarity with the basics of the science underpinning drug discovery 
  • Ability to use MS Office and database software
  • Willingness to travel between sites



About Discovery Services
  • Discovery from our company is industry-proven in the successful development of novel therapies, with over 320 patents and 74 preclinical drug candidates delivered to our sponsors in the past 17 years.
  •  Backed by more than 650 scientists, our comprehensive, integrated portfolio employs the latest technology and platforms to provide chemistry, biology, and pharmacology services that support clients from the earliest stages of hit identification all the way through to IND. 
  • Our client-focused, collaborative approach creates true partnerships that anticipate challenges, overcome obstacles, and move us forward together on the journey of getting new drugs to market.



About us:
  • Our company is an early-stage contract research organization (CRO). 
  • We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. 
  • Our company  also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. 
  • Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.
  • With over 11,000 employees within 70 facilities in 18 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges. 
  • Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2016, revenue increased by 23.3% to $1.68 billion from $1.36 billion in 2015. 
  • We are passionate about our role in improving the quality of people’s lives. 
  • Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~70% of the drugs approved by the FDA in 2016.



Equal Employment Opportunity
Our company  is an Equal Opportunity Employer M/F/Disabled/Vet